Skip to main content
Log in

Characterization of the Biodistribution and Systemic Absorption of TT-173, a New Hemostatic Agent of Recombinant Human Tissue Factor, Using Radiolabeling with 18F

  • Original Research Article
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background and Objectives

TT-173 is the first topical hemostatic agent based on tissue factor. To prevent thromboembolic events and intravascular coagulation it is necessary to rule out the systemic absorption of new bioactive hemostats. Here, we radiolabeled TT-173 with [18F]SBF to characterize its systemic absorption and biodistribution.

Methods

A group of rats were administered intravenously with [18F]TT-173 and were subjected to a positron emission tomography study. A second group of animals received the [18F]TT-173 topically over a skin lesion in the flank. Topical absorption was quantified and the biodistribution patterns observed were compared.

Results

After topical application, low amounts of [18F]TT-173 were absorbed and distributed without relevant accumulation in any organ. On the other hand, after intravenous injection, [18F]TT-173 accumulated in lungs, liver and spleen, consistent with intravascular clot formation and the posterior capillary trapping and phagocytosis by the reticuloendothelial system. In both cases, a substantial concentration of radioactive product was found in urine consistent with renal excretion of degradation products of [18F]TT-173.

Conclusions

After topical application, [18F]TT-173 did not show a significant systemic accumulation in animal organs. Minor radioactive concentration found in lungs, liver and spleen likely corresponds with fragments of the product without procoagulant activity. Radiolabeling with [18F]SFB enables the characterization of systemic absorption and biodistribution of new topical hemostats like TT-173.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Koea JB, Batiller J, Patel B, Shen J, Hammond J, Hart J, Fischer C, Garden OJ. A phase III, randomized, controlled, superiority trial evaluating the fibrin pad versus standard of care in controlling parenchymal bleeding during elective hepatic surgery. HPB (Oxford). 2013;15:61–70. doi:10.1111/j.1477-2574.2012.00583.x.

    Article  Google Scholar 

  2. Falez F, Meo A, Panegrossi G, Favetti F, La Cava F, Casella F. Blood loss reduction in cementless total hip replacement with fibrin spray or bipolar sealer: a randomised controlled trial on ninety five patients. Int Orthop. 2013;37:1213–7. doi:10.1007/s00264-013-1903-8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Bruckner BA, Blau LN, Rodriguez L, Suarez EE, Ngo UQ, Reardon MJ, Loebe M. Microporous polysaccharide hemosphere absorbable hemostat use in cardiothoracic surgical procedures. J. Cardiothorac. Surg. 2014;9:134. doi:10.1186/s13019-014-0134-4.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kilty SJ, Al-Hajry M, Al-Mutairi D, Bonaparte JP, Duval M, Hwang E, Tse D. Prospective clinical trial of gelatin-thrombin matrix as first line treatment of posterior epistaxis. Laryngoscope. 2014;124:38–42. doi:10.1002/lary.24240.

    Article  CAS  PubMed  Google Scholar 

  5. Lo GH, Lin CW, Perng DS, Chang CY, Lee CT, Hsu CY, Wang HM, Lin HC. A retrospective comparative study of histoacryl injection and banding ligation in the treatment of acute type 1 gastric variceal hemorrhage. Scand J Gastroenterol. 2013;48:1198–204. doi:10.3109/00365521.2013.832792.

    Article  PubMed  Google Scholar 

  6. King DR. Thirty consecutive uses of a hemostatic bandage at a US Army combat support hospital and forward surgical team in Operation Iraqi Freedom. J Trauma. 2011;71:1775–8. doi:10.1097/TA.0b013e3182231615.

    Article  PubMed  Google Scholar 

  7. Saha SP, Muluk S, Schenk W 3rd, Dennis JW, Ploder B, Grigorian A, Presch I, Goppelt A. A prospective randomized study comparing fibrin sealant to manual compression for the treatment of anastomotic suture-hole bleeding in expanded polytetrafluoroethylene grafts. J Vasc Surg. 2012;56:134–41. doi:10.1016/j.jvs.2012.01.009.

    Article  PubMed  Google Scholar 

  8. Nasso G, Piancone F, Bonifazi R, Romano V, Visicchio G, De Filippo CM, Impiombato B, Fiore F, Bartolomucci F, Alessandrini F, Speziale G. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg. 2009;88:1520–6. doi:10.1016/j.athoracsur.2009.07.014.

    Article  PubMed  Google Scholar 

  9. Bochicchio GV, Gupta N, Porte RJ, Renkens KL, Pattyn P, Topal B, Troisi RI, Muir W, Chetter I, Gillen DL, Zuckerman LA, Frohna PA. The FINISH-3 trial: a phase 3, international, randomized, single-blind, controlled trial of topical fibrocaps in intraoperative surgical hemostasis. J Am Coll Surg. 2015;220:70–81. doi:10.1016/j.jamcollsurg.2014.09.019.

    Article  PubMed  Google Scholar 

  10. Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg. 2010;251:217–28. doi:10.1097/SLA.0b013e3181c3bcca.

    Article  PubMed  Google Scholar 

  11. Adams JD, Jones S, Brost BC. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report. J. Reprod. Med. 2001;46:909–12.

    CAS  PubMed  Google Scholar 

  12. Naoum JJ. Immune-mediated coagulopathy: a case report. Pharmacotherapy. 2009;29:13S–7S. doi:10.1592/phco.29.pt2.13S.

    Article  PubMed  Google Scholar 

  13. Lee KR, Drury I, Vitarbo E, Hoff JT. Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage. J Neurosurg. 1997;87:73–8.

    Article  CAS  PubMed  Google Scholar 

  14. Liu DZ, Ander BP, Xu H, Shen Y, Kaur P, Deng W, Sharp FR. Blood-brain barrier breakdown and repair by Src after thrombin-induced injury. Ann. Neurol. 2010;67:526–33. doi:10.1002/ana.21924.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27:1687–93.

    Article  CAS  PubMed  Google Scholar 

  16. Morrissey JH, Comp PC. Treatment of bleeding with modified tissue factor in combination with FVIIa. U.S. Patent 5,374,617 (December 20 1994).

  17. Neuenschwander PF, Morrissey JH. Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIa Gla domain is dispensable for binding to tissue factor but important for activation of factor X. J Biol Chem. 1994;269:8007–13.

    CAS  PubMed  Google Scholar 

  18. Smith SA, Morrissey JH. Rapid and efficient incorporation of tissue factor into liposomes. J Thromb Haemost. 2004;2:1155–62.

    Article  CAS  PubMed  Google Scholar 

  19. Murat J, Rodríguez JR. Phospholipid- enriched vesicles bearing tissue factor having haemostatic activities and uses thereof. WO2011131658 (A1)—2011-10-27.

  20. López-López J, Jané-Salas E, Santamaría A, González-Navarro B, Arranz-Obispo C, López R, Miquel I, Arias B, Sánchez P, Rincón E, Rodríguez JR, Rojas S, Murat J. TETIS study: evaluation of new topical hemostatic agent TT-173 in tooth extraction. Clin Oral Investig. 2016; 20:1055–63. doi:10.1007/s00784-015-1586-1

    Article  Google Scholar 

  21. Uchigasaki S, Takahashi H, Suzuki T. A case of delayed death after accidental intravenous injection of thrombin. Int J Legal Med. 1998;111:202–4.

    Article  CAS  PubMed  Google Scholar 

  22. D’Ayala M, Smith R, Zanieski G, Fahoum B, Tortólani AJ. Acute arterial occlusion after ultrasound-guided thrombin injection of a common femoral artery pseudoaneurysm with a wide, short neck. Ann Vasc Surg. 2008;22:473–5. doi:10.1016/j.avsg.2007.09.018.

    Article  PubMed  Google Scholar 

  23. Pusateri AE, Holcomb JB, Bhattacharyya SN, Harris RA, Gomez RR, MacPhee MJ, Enriquez JI, Delgado AV, Charles NC, Hess JR. Different hypotensive responses to intravenous bovine and human thrombin preparations in swine. J Trauma. 2001;50:83–90.

    Article  CAS  PubMed  Google Scholar 

  24. Rojas S, Nolis P, Gispert JD, Spengler J, Albericio F, Herance JR, Abad S. Efficient cysteine labelling of peptides with N-succinimidyl 4-[18F]fluorobenzoate: stability study and in vivo biodistribution in rats by positron emission tomography (PET). RSC Adv. 2013;3:8028–36. doi:10.1039/c3ra40754c.

    Article  CAS  Google Scholar 

  25. Abad S, Nolis P, Gispert JD, Spengler J, Albericio F, Rojas S, Herance JR. Rapid and high-yielding cysteine labelling of peptides with N-succinimidyl 4-[18F]fluorobenzoate. Chem Commun (Camb). 2012;48:6118–20. doi:10.1039/c2cc32095a.

    Article  CAS  Google Scholar 

  26. Rojas S, Gispert JD, Martín R, Abad S, Menchón C, Pareto D, Víctor VM, Alvaro M, García H, Herance JR. Biodistribution of amino-functionalized diamond nanoparticles. In vivo studies based on 18F radionuclide emission. ACS Nano. 2011;5:5552–9. doi:10.1021/nn200986z.

    Article  CAS  PubMed  Google Scholar 

  27. Rojas S, Gispert JD, Menchón C, Baldoví HG, Buaki-Sogo M, Rocha M, Abad S, Victor VM, García H, Herance JR. Novel methodology for labelling mesoporous silica nanoparticles using the 18F isotope and their in vivo biodistribution by positron emission tomography. J Nanopart Res. 2015;17:131. doi:10.1007/s11051-015-2938-0.

    Article  Google Scholar 

  28. Mäding P, Füchtner F, Wüst F. Module-assisted synthesis of the bifunctional labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate ([(18)F]SFB). Appl Radiat Isot. 2005;63:329–32.

    Article  PubMed  Google Scholar 

  29. Hamed S, Ullmann Y, Masoud M, Hellou E, Khamaysi Z, Teot L. Topical erythropoietin promotes wound repair in diabetic rats. J. Invest. Dermatol. 2010;130:287–94. doi:10.1038/jid.2009.219.

    Article  CAS  PubMed  Google Scholar 

  30. Banzato A, Rondina M, Meléndez-Alafort L, Zangoni E, Nadali A, Renier D, Moschini G, Mazzi U, Zanovello P, Rosato A. Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. Nucl Med Biol. 2009;36:525–33. doi:10.1016/j.nucmedbio.2009.02.005.

    Article  CAS  PubMed  Google Scholar 

  31. Laznicek M, Laznickova A, Cozikova D, Velebny V. Preclinical pharmacokinetics of radiolabelled hyaluronan. Pharmacol. Rep. 2012;64:428–37.

    Article  CAS  PubMed  Google Scholar 

  32. Wu H, Liang S, Liu S, Pan Y, Cheng D, Zhang Y. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals. Nucl Med Commun. 2013;34:701–8. doi:10.1097/MNM.0b013e3283614187.

    Article  PubMed  Google Scholar 

  33. Rojas S, Gispert JD, Abad S, Buaki-Sogo M, Victor VM, Garcia H, Herance JR. In vivo biodistribution of amino-functionalized ceria nanoparticles in rats using positron emission tomography. Mol Pharm. 2012;9:3543–50. doi:10.1021/mp300382n.

    Article  CAS  PubMed  Google Scholar 

  34. Herance JR, Gispert JD, Abad S, Victor VM, Pareto D, Torrent E, Rojas S. Erythrocytes labeled with [(18) F]SFB as an alternative to radioactive CO for quantification of blood volume with PET. Contrast Media Mol Imaging. 2013;8:375–81. doi:10.1002/cmmi.1533.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Santiago Rojas or José Raúl Herance.

Ethics declarations

Funding

This work has been funded by Thrombotargets Europe S.L. José Raúl Herance is hired by Fondo de Investigación Sanitaria. Instituto Carlos III. Under the program Miquel Servet I and the European Regional Development Fund (ERDF) CP13/00252.

Conflict of interest

José Raúl Herance and Juan D. Gispert have no conflicts of interest. The other authors are employed by Thrombotargets Europe S.L. However, the company does not have any commercial interest related with the publication of this work.

Ethical Approval

The experimental procedures were carried out following the European Directives and the Spanish Legislation regarding the use of animals for scientific purposes and with the specific approval of the Ethical Committee of Animal Experimentation of Barcelona Biomedical Research Park.

Additional information

S. Rojas and J. R. Herance equally contributed to the work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rojas, S., Herance, J.R., Gispert, J.D. et al. Characterization of the Biodistribution and Systemic Absorption of TT-173, a New Hemostatic Agent of Recombinant Human Tissue Factor, Using Radiolabeling with 18F. Eur J Drug Metab Pharmacokinet 42, 583–592 (2017). https://doi.org/10.1007/s13318-016-0366-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13318-016-0366-x

Keywords

Navigation